Table 3.

Ongoing clinical trials combining antiangiogenics

Drug 1Drug 2PhaseCancerClinicalTrials.gov identifier
ABT-510 (TSP-1 analog)BevacizumabIAdvanced solid cancer, solid tumorsNCT00276562
AMG-386 (ANGPT1/2 antibody)AMG-706IAdvanced solid cancer, solid tumorsNCT00861419
Bevacizumab
Sorafenib
Sunitinib
BevacizumabPazopanibIRenalNCT00992121
CVX-060 (ANGP2 binding peptide)SunitinibIRenalNCT00982657
FosbretabulinBevacizumabIHigh-grade gliomasNCT01052363
OmbrabulinBevacizumabIAdvanced solid cancer, solid tumorsNCT01193595
VandetanibBevacizumab (+CapOx)IColorectalNCT00532909
VandetanibBevacizumabIAdvanced solid cancer, solid tumors, or lymphomaNCT00734890
Etaracizumab (anti-a5b3 integrin)BevacizumabI/IIRenalNCT00684996
BevacizumabSorafenib (+oxaliplatin)I/IIMelanomaNCT00538005
SorafenibThalidomideI/IIHepatocellularNCT00971126
AMG-386Bevacizumab (+paclitaxel)IIBreastNCT00511459
AMG-386 (ANGPT1/2 antibody)SunitinibIIRenalNCT00853372
BevacizumabSorafenibIIRenalNCT00126503
BevacizumabThalidomideIIMultiple myelomaNCT00022607
Combretastatin (CA4P)BevacizumabIIOvarianNCT01305213
Combretastatin (CA4P)BevacizumabIILungNCT00653939
SorafenibBevacizumabIIColorectalNCT00826540
SorafenibBevacizumabIIBreastNCT00632541
SorafenibBevacizumabIILiverNCT00881751
SorafenibBevacizumabIIGBMNCT00621686

Abbreviations: CapOx, capecitabine and oxaliplatin.